1-[3-(2-hydroxyethyl)phenyl]-2-imidazolidinone | 844903-55-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: 1-[3-(2-hydroxyethyl)phenyl]-2-imidazolidinone
• 英文别名: 1-[3-(2-hydroxyethyl)phenyl]imidazolidin-2-one
• CAS: 844903-55-5
• 化学式: C₁₁H₁₄N₂O₂
• 分子量: 206.244
• InChiKey: VVHXVHRQSMCPTC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  52.6
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-[3-(2-hydroxyethyl)phenyl]-2-imidazolidinone 在 碳酸甲丙酯 、 N,N-二异丙基乙胺 作用下， 以 丙腈 为溶剂， 反应 10.5h， 生成 1-[3-[2-[4-(2-甲基-5-喹啉基)-1-哌嗪基]乙基]苯基]-2-咪唑烷酮
  参考文献：
  名称：

  Route Selection and Process Development for a 5-Piperazinylquinaldine Derivative for the Treatment of Depression and Anxiety

  摘要：

  1-(3-{2-[4-(2-Methyl-5-quinolinyl)-1-piperazinyl]ethyl}phenyl)-2-imidazolidinone, 1, was identified as a potential drug for the treatment of depression and anxiety. Herein is described the work carried out to select the manufacturing route and the process research studies to optimize the key stages of route B. A particular focus is given to the genotoxic impurities, related to this route, as one of the intermediates of the manufacturing route was genotoxic and many genotoxic impurities can be formed in the process. Quality by Design principles were applied for the definition of the control strategy of these impurities.

  DOI：

  10.1021/op200140v
• 作为产物：
  描述：

  methyl [3-(2-oxo-1-imidazolidinyl)phenyl]acetate 在 锂硼氢 、 水 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 4.5h， 以75%的产率得到1-[3-(2-hydroxyethyl)phenyl]-2-imidazolidinone
  参考文献：
  名称：

  [EN] QUINOLINE AND QUINAZOLINE DERIVATIVES HAVING AFFINITY FOR 5HT1-TYPE RECEPTORS
  [FR] DERIVES DE QUINOLINE ET DE QUINAZOLINE PRESENTANT UNE AFFINITE VIS-A-VIS DES RECEPTEURS DU TYPE 5HT1

  摘要：

  提供了式(I)的化合物及其药用盐：其中R1、m、X、R2、n、W、p、Y、Z、R3、R4、R5和q的含义如描述中所定义。还公开了制备方法以及在治疗中的用途，特别是用于抑郁症或焦虑等中枢神经系统疾病。

  公开号：

  WO2005014552A1

文献信息

• Quinoline and quinazoline derivatives having affinity for 5ht1-type receptors
  申请人：Bergauer Markus

  公开号：US20060229312A1

  公开（公告）日：2006-10-12

  Compounds of formula (I) and pharmaceutically acceptable salts thereof are provided: wherein R 1 , m, X, R 2 , n, W, p, Y, Z, R 3 , R 4 , R 5 and q have the meanings as defined in the description. Methods of preparation and uses thereof in therapy, particularly for CNS disorders such as depression or anxiety, are also disclosed.

  提供式(I)的化合物和药学上可接受的盐：其中R1，m，X，R2，n，W，p，Y，Z，R3，R4，R5和q的含义如描述中所定义。还公开了制备方法以及在治疗中的用途，特别是用于中枢神经系统疾病，如抑郁症或焦虑症。
• Quinoline and quinazoline derivatives having affinity for 5HT1-type receptors
  申请人：Glaxo Group Limited

  公开号：US07279481B2

  公开（公告）日：2007-10-09

  Compounds of formula (I) and pharmaceutically acceptable salts thereof are provided: wherein R1, m, X, R2, n, W, p, Y, Z, R3, R4, R5 and q have the meanings as defined in the description. Methods of preparation and uses thereof in therapy, particularly for CNS disorders such as depression or anxiety, are also disclosed.

  提供化学式（I）的化合物及其药学上可接受的盐： 其中R1，m，X，R2，n，W，p，Y，Z，R3，R4，R5和q的含义如描述中所定义。还公开了其制备方法和在治疗中的用途，特别是用于中枢神经系统疾病，如抑郁症或焦虑症。
• QUINOLINE AND QUINAZOLINE DERIVATIVES HAVING AFFINITY FOR 5HT1-TYPE RECEPTORS
  申请人：Bergauer Markus

  公开号：US20070167423A1

  公开（公告）日：2007-07-19

  Compounds of formula (I) and pharmaceutically acceptable salts thereof are provided: wherein R 1 , m, X, R 2 , n, W, p, Y, Z, R 3 , R 4 , R 5 and q have the meanings as defined in the description. Methods of preparation and uses thereof in therapy, particularly for CNS disorders such as depression or anxiety, are also disclosed.

  提供了式(I)的化合物及其药学上可接受的盐： 其中，R1、m、X、R2、n、W、p、Y、Z、R3、R4、R5和q的含义如描述中定义的那样。还公开了其制备方法和在治疗中的用途，特别是用于中枢神经系统疾病如抑郁症或焦虑症。
• Quinoline and Quinazoline Derivatives Having Affinity for 5HT1-Type Receptors
  申请人：Bergauer Markus

  公开号：US20100204273A1

  公开（公告）日：2010-08-12

  Disclosed are methods for use of compounds of formula (I) in the treatment of CNS disorders such as dysthymia, schizophrenia, panic disorder, obsessive compulsive disorder, post-traumatic stress disorder, pain, and memory disorders: wherein R 1 , m, X, R 2 , n, W, p, Y, Z, R 3 , R 4 , R 5 and q have the meanings as defined in the description.

  本发明揭示了使用式（I）化合物治疗中枢神经系统疾病，如心境不良、精神分裂症、惊恐障碍、强迫症、创伤后应激障碍、疼痛和记忆障碍的方法：其中R1，m，X，R2，n，W，p，Y，Z，R3，R4，R5和q的含义如描述中定义的那样。
• Application of the Quality by Design Principles for the Development of the Crystallization Process for a Piperazinyl-Quinoline and Definition of the Control Strategy for Form 1
  作者：Zadeo Cimarosti、Sara Rossi、Davide Tramarin、Gilles Laval、Paolo Stabile、Nicola Giubellina、William Maton、Brigida Allieri、Francesca Campi、Jason Cooke、Pieter Westerduin

  DOI：10.1021/op300126e

  日期：2012.10.19

  have potentially formed in the crystallization process. The principles of quality by design (QbD) were applied to generate the process understanding and to define the control strategy for the control of the formation of the solvate during the crystallization. The application of process analytical technology (PAT) tools was key in achieving the desired process control.

  该贡献描述了为开发取代的哌嗪基-喹啉（1）的稳健结晶方法而进行的研究，该化合物可能在治疗抑郁症中具有活性。这些研究包括控制可能在结晶过程中形成的溶剂化物。设计中的质量原理（QbD）用于产生对工艺的理解，并定义用于控制结晶过程中溶剂化物形成的控制策略。过程分析技术（PAT）工具的应用是实现所需过程控制的关键。